About Us

Company Overview

BriSTAR Immunotech is a clinical-stage cell therapy company dedicated to the development and commercialization of innovative engineered T cell immunotherapy products for the treatment of cancer and viral infections.

BriSTAR Immunotech was founded in 2018 by internationally-renowned molecular immunologist, Dr. Lin Xin and his team at Tsinghua University.

Development history

2023

Submitting a new IND

Preclinical data AACR released

Two solid tumor products entered early clinical stage

2022

B+ round financing

Submitted the first IND

New CMC & QC facilities completed

2021

B-round financing

Paper on STAR-T published

IIT date presented at EHA conference

2020

A+round financing

Moved in Beijing R&D headquarter

IIT Data presented in ASH conference

2019

A-round financing

Initiated STAR-T IIT

2018

Company was founded (Dr. Lin Xin)

Angel round fiInancing

Pre-A round financing

Initiated TCR-T IIT